Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

P 2004

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN et. al.

Základní údaje

Originální název

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Název česky

Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors

Autoři

GUZI, Timothy (840 Spojené státy), Kamil PARUCH (203 Česká republika, garant), Michael DWYER (840 Spojené státy), Ronald DOLL (840 Spojené státy), Viyyoor GIRIJAVALLABHAN (840 Spojené státy), Lawrence DILLARD (840 Spojené státy), Vinh TRAN (840 Spojené státy), Zhen HE (840 Spojené státy), Ray JAMES (840 Spojené státy) a Haengsoon PARK (840 Spojené státy)

Vydání

Číslo: WO 2004/022559 A1, Vydavatel: World Intellectual Property Organization, Místo vydání: USA, Název vlastníka: Schering Plough; Pharmacopeia, 2004

Další údaje

Jazyk

angličtina

Typ výsledku

Patent

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14310/04:00035999

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova česky

cyclin dependent kinase; inhibitor; pyrazolopyrimidine

Klíčová slova anglicky

cyclin dependent kinase; inhibitor; pyrazolopyrimidine

Štítky

Cyclin dependent kinase, inhibitor, pyrazolopyrimidine

Změněno: 25. 6. 2009 10:31, doc. Mgr. Kamil Paruch, Ph.D.

Anotace

ORIG CZ

V originále

The title pyrazolo[1,5-a]pyrimidines [I; R = (un)substituted heteroaryl; R2 = (un)substituted alkyl, alkynyl, aryl, heteroaryl, alkynylalkyl, CF3, heterocyclylalkyl, alkynylalkyl, cycloalkyl, CO2R4, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CO2R4, CONR5R6, each (un)substituted alkyl, alkynyl, cycloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, or heteroaryl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepd. In its many embodiments, the present invention also provides methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds. I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease assocd. with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.

Česky

viz Anotace

Citovat

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES a Haengsoon PARK. Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors. 2004. Patent. Číslo: WO 2004/022559 A1. Vydavatel: World Intellectual Property Organization. Místo vydání: USA. Název vlastníka: Schering Plough; Pharmacopeia. Datum registrace: 3. 9. 2003. Datum přijetí: 18. 3. 2004.

@misc{838407,
   author = {Guzi, Timothy and Paruch, Kamil and Dwyer, Michael and Doll, Ronald and Girijavallabhan, Viyyoor and Dillard, Lawrence and Tran, Vinh and He, Zhen and James, Ray and Park, Haengsoon},
   keywords = {cyclin dependent kinase; inhibitor; pyrazolopyrimidine},
   language = {eng},
   title = {Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors},
   year = {2004}
}

TY  - PAT
ID  - 838407
AU  - Guzi, Timothy - Paruch, Kamil - Dwyer, Michael - Doll, Ronald - Girijavallabhan, Viyyoor - Dillard, Lawrence - Tran, Vinh - He, Zhen - James, Ray - Park, Haengsoon
PY  - 2004
TI  - Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors
KW  - cyclin dependent kinase
KW  - inhibitor
KW  - pyrazolopyrimidine
N2  - The title pyrazolo[1,5-a]pyrimidines [I; R = (un)substituted heteroaryl; R2 = (un)substituted alkyl, alkynyl, aryl, heteroaryl, alkynylalkyl, CF3, heterocyclylalkyl, alkynylalkyl, cycloalkyl, CO2R4, etc., wherein aryl is optionally substituted; R3 = H, halogen, NR5R6, CO2R4, CONR5R6, each (un)substituted alkyl, alkynyl, cycloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, or heteroaryl, etc.; R4 = H, halo, alkyl; R5 = H, alkyl; R6 = H, each (un)substituted alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroarylalkyl; or R5 and R6 in the moiety -NR5R6, may be joined together to form an (un)substituted cycloalkyl or heterocyclyl] or pharmaceutically acceptable salts or solvates thereof are prepd. In its many embodiments, the present invention also provides methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds. I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with cyclin dependent kinase using such compds. I or pharmaceutical compns. The disease assocd. with cyclin dependent kinase is selected from the group consisting of; (1) cancer of the bladder, breast, colon, kidney, liver, lung, small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; (2) leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkitt's lymphoma; (3) acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia; (4) fibrosarcoma and rhabdomyosarcoma; (5) astrocytoma, neuroblastoma, glioma and schwannomas; and (6) melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma.
ER  -

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Ronald DOLL, Viyyoor GIRIJAVALLABHAN, Lawrence DILLARD, Vinh TRAN, Zhen HE, Ray JAMES a Haengsoon PARK. \textit{Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors}. 2004. Patent. Číslo: WO 2004/022559 A1. Vydavatel: World Intellectual Property Organization. Místo vydání: USA. Název vlastníka: Schering Plough; Pharmacopeia. Datum registrace: 3. 9. 2003. Datum přijetí: 18. 3. 2004.

Podrobný výpis o publikaci